MX2017006242A - Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. - Google Patents

Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.

Info

Publication number
MX2017006242A
MX2017006242A MX2017006242A MX2017006242A MX2017006242A MX 2017006242 A MX2017006242 A MX 2017006242A MX 2017006242 A MX2017006242 A MX 2017006242A MX 2017006242 A MX2017006242 A MX 2017006242A MX 2017006242 A MX2017006242 A MX 2017006242A
Authority
MX
Mexico
Prior art keywords
mass spectrometry
determination
glycosaminoglycans
medical conditions
various medical
Prior art date
Application number
MX2017006242A
Other languages
English (en)
Inventor
Ann Barbier
Patrick Anthony John Haslett
NAIMY Hicham
Qiu Yongchang
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2017006242A publication Critical patent/MX2017006242A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Detector los glicosaminoglicanos (GAG) y/o determinar el nivel de uno o más glicosaminoglicanos puede ser útil, por ejemplo, en la identificación o monitoreo de diversas afecciones médicos, el estado de pacientes que padecen diversas afecciones médicas y/o la respuesta al tratamiento de individuos que padecen diversas afecciones medicas; la presente invención proporciona métodos para detector los glicosaminoglicanos y/o determinar el nivel de glicosaminoglicanos mediante el use de, por ejemplo, espectrometría de masas.
MX2017006242A 2014-11-14 2015-11-13 Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. MX2017006242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462080154P 2014-11-14 2014-11-14
PCT/US2015/060714 WO2016077775A1 (en) 2014-11-14 2015-11-13 Determination of glycosaminoglycan levels by mass spectrometry

Publications (1)

Publication Number Publication Date
MX2017006242A true MX2017006242A (es) 2018-01-23

Family

ID=54754780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006242A MX2017006242A (es) 2014-11-14 2015-11-13 Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.

Country Status (10)

Country Link
US (1) US10578624B2 (es)
EP (1) EP3218722A1 (es)
JP (1) JP6693954B2 (es)
CN (1) CN107003324B (es)
AU (1) AU2015346064B2 (es)
CA (1) CA2967382A1 (es)
EA (1) EA035784B1 (es)
MA (1) MA40954A (es)
MX (1) MX2017006242A (es)
WO (1) WO2016077775A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6973714B2 (ja) * 2017-06-09 2021-12-01 国立大学法人北海道大学 ニーマン・ピック病ｃ型の診断を補助する方法、ニーマン・ピック病ｃ型に対する治療効果の判定を補助する方法並びにニーマン・ピック病ｃ型治療薬のスクリーニング方法
TW201925236A (zh) * 2017-10-02 2019-07-01 美商戴納立製藥公司 包含酶替代療法酶之融合蛋白
CN114965822B (zh) * 2017-10-27 2024-06-04 齐鲁制药有限公司 高效测定神经节苷脂gm1及其杂质的药物分析方法
CN107991414A (zh) * 2017-12-28 2018-05-04 山东大学 一种舒洛地特的电泳亲水相互作用色谱质谱联用检测方法
JP7361256B2 (ja) * 2018-08-21 2023-10-16 Ｊｃｒファーマ株式会社 コンドロイチン硫酸の分析法
CN109541115B (zh) * 2018-11-28 2021-04-20 西北大学 唾液酸化糖链同分异构体的高分辨顺序分离和准确定量分析方法
JP2021036232A (ja) * 2019-08-23 2021-03-04 Ｊｃｒファーマ株式会社 脳脊髄液に含まれるＨｅｘ４，ｌｙｓｏ−ＧＭ１，Ｆｕｃ−ＧｌｃＮＡｃ−Ａｓｎ，及びｌｙｓｏ−ｓｕｌｆａｔｉｄｅの定量法
CN111721872B (zh) * 2020-06-24 2021-06-25 山东大学 一种肝素与硫酸乙酰肝素的鉴别方法及应用
WO2022125560A1 (en) * 2020-12-07 2022-06-16 The Nemours Foundation Elevation of glycosaminoglycans in subjects without mucopolysaccharidosis
CN113092604B (zh) * 2021-03-18 2022-04-12 福建省水产研究所（福建水产病害防治中心） 水产品中三种常用麻醉剂的快速检测方法
CN115032377B (zh) * 2022-08-11 2022-11-01 裕菁科技(上海)有限公司 一种粘多糖贮积症生物标记物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3698563B2 (ja) * 1998-09-22 2005-09-21 生化学工業株式会社 グリコサミノグリカンの測定方法及び測定キット
JP2003265196A (ja) * 2002-03-15 2003-09-24 Seikagaku Kogyo Co Ltd ムコ多糖症のスクリーニング方法
AUPS293002A0 (en) * 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
US20050238536A1 (en) * 2004-04-21 2005-10-27 Striepeke Steven K Device and method for measuring glycosaminoglycans in body fluids
JP4965999B2 (ja) * 2005-12-27 2012-07-04 セント ルイス ユニバーシティ ムコ多糖症の診断方法
US9029530B2 (en) * 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
IL284599B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Methods and preparations for administration of iduronate-2-sulfatase to the central nervous system
CN104114686A (zh) * 2011-11-07 2014-10-22 夏尔人类遗传性治疗公司 Sanfilippo综合征的生物标志物及其用途
CN103713057B (zh) * 2013-12-12 2015-07-08 中国海洋大学 一种降解硫酸乙酰肝素及检测其二糖组成的方法

Also Published As

Publication number Publication date
US10578624B2 (en) 2020-03-03
MA40954A (fr) 2017-09-19
AU2015346064B2 (en) 2021-09-23
CN107003324B (zh) 2019-09-24
EP3218722A1 (en) 2017-09-20
WO2016077775A1 (en) 2016-05-19
CA2967382A1 (en) 2016-05-19
JP2017535774A (ja) 2017-11-30
EA035784B1 (ru) 2020-08-10
AU2015346064A1 (en) 2017-05-18
CN107003324A (zh) 2017-08-01
US20170350900A1 (en) 2017-12-07
JP6693954B2 (ja) 2020-05-13
EA201790769A1 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
MX2017006242A (es) Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.
PH12017502153A1 (en) Diagnostic methods for t cell therapy
MX2020005165A (es) Biogenesis de miarn en exosomas para diagnostico y terapia.
PL3212208T3 (pl) Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia
WO2016040775A3 (en) Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
MX2021001659A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
MA40390A (fr) Procédés d'analyse impliquant des nanoparticules dissociables
MX2016009060A (es) Metodos y sistemas para determinar el riesgo de falla cardiaca.
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
IL255440A0 (en) Methods and preparations for the diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
IL249237B (en) Ornithodorus Mobate complement inhibitor for use in the treatment of complement-induced diseases in patients with the c5 polymorphism
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2016003002A (es) Metodos para determinar la respuesta a la terapia.
MX2020002216A (es) Metodos y composiciones para detectar y tratar endometriosis.
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX369175B (es) Métodos para detectar mutantes de akt resistentes a fármacos.
MX2015001648A (es) Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
MX2015017535A (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.